Arix Bioscience PLC (LON:ARIX), the venture capital company focused on the biotechnology sector, said its portfolio company, Autolus Therapeutics (NASDA:AUTL), has priced its offering of new American Depositary Shares (ADS).
In total it has put up for sale 7.25mln ADSs at a price of US$11 each in an underwritten offer that will bring in a ‘gross’ US$80mln.
The underwriters have a 30-day option to acquire an additional 1.088mln shares.
Arix retains a 6.5% stake worth US$42mln (£32mln) and its chief executive, Dr Joe Anderson, remains on the Autolus board.